Low Performance of Hepatitis Delta Virus Testing Among 2 National Cohorts of Chronic Hepatitis B Patients in the United States
Hepatitis delta virus (HDV) infection is associated with more aggressive disease progression in patients with chronic hepatitis B (CHB) infection (1–7). Suboptimal awareness and nonroutine HDVtesting amongCHBpatients persists. Recent studies estimate the global HDV prevalence to be approximately 12 million (8). Studies evaluating HDV prevalence in the United States are limited, and lack of an effective national CHB surveillance system, compounded by suboptimal HDV testing and nonexistent reporting systems forHDV, contributes to uncertainly aboutHDV burden. Data from Stockdale et al (8,9) reported an HDV prevalence of 5.9% among US adults with CHB, translating to an estimated 142,000 adults with HDV. However, few large studies exist evaluating HDV testing patterns among US adults with CHB.